Search hospitals > Quebec > MONTREAL
Novartis Investigative Site
Claim this profileMONTREAL, Quebec H3T 1E2
Global Leader in Breast Cancer
Global Leader in Pancreatic Cancer
Conducts research for Multiple Sclerosis
Conducts research for Relapse
Conducts research for Cancer
289 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Multiple Sclerosis, Relapse, Cancer and other specialties. Novartis Investigative Site is involved with conducting 289 clinical trials across 349 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Breast Cancer
Global LeaderStage III
Stage IV
HER2 negative
2Pancreatic Cancer
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Clinical Trials running at Novartis Investigative Site
Prostate Cancer
Multiple Sclerosis
Breast Cancer
Follicular Lymphoma
Relapse
Pancreatic Cancer
Small Cell Lung Cancer
Spinal Muscular Atrophy
Chronic Myeloid Leukemia
Motor and sensory neuropathy
Long-Term Safety of AAA617
for Prostate Cancer
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Recruiting3 awards Phase 4
Lutetium (177Lu) Vipivotide Tetraxetan
for Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Recruiting2 awards Phase 36 criteria
[225Ac]Ac-ETN029
for Cancer
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Recruiting1 award Phase 11 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Multiple Sclerosis, Relapse, Cancer and other specialties. Novartis Investigative Site is involved with conducting 289 clinical trials across 349 conditions. There are 0 research doctors associated with this hospital, such as .
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.